Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 268 clinical trials
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: To determine the effect of venglustat on the …

cystic renal diseases
cyst
urine osmolality
fatigue
antihypertensive therapy
  • 0 views
  • 19 Feb, 2024
  • 81 locations
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (2 to <18 years old).

bone disease
osteopenia
replacement therapy
alglucerase
platelet count
  • 0 views
  • 19 Feb, 2024
  • 19 locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

adjuvant
immunological adjuvant
HER2
oestrogen receptor positive breast cancer
estrogen receptor-positive breast cancer
  • 0 views
  • 19 Feb, 2024
  • 126 locations
SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival …

advanced breast cancer
HER2
solid tumour
letrozole
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 5 locations
A Communication Enhancing Intervention to Improve Patients' Perception of Physiotherapy Consultations

The aim of this study is to test the effectiveness of a single training session in communication skills at improving patients' perceptions of physiotherapy consultations.

physiotherapy
  • 0 views
  • 19 Feb, 2024
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:Screening period: 2 to 4 weeks.Treatment period: 24 weeks.Post-intervention follow-up period: 16 weeks.

  • 0 views
  • 14 May, 2025
A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

The purpose of this pilot study is to evaluate a high intensity walking intervention in older surgical candidates with kidney or thoracic disease and pre-frailty or frailty.

  • 0 views
  • 19 Feb, 2024
Unannounced Meal Handling of Advanced Closed Loop Insulin Delivery in Monitored Condition

The study will follow participants for the periods of 3 months while using an advanced hybrid closed loop algorithm in free living conditions . Each period will have a different meal handling protocols.

insulin
type 1 diabetes mellitus
  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

Secondary objectives include evaluating the effect of mitapivat on electrocardiogram (ECG) parameters, including concentration-QT interval corrected for heart rate (C-QTc) analysis under fasted conditions. The study will include a 28-day screening period, four 7-day treatment periods. Participants will receive a follow-up telephone call within 28 (1) days after the last …

12 lead ECG
drug test
infertility
oral contraceptives
body mass index
  • 0 views
  • 19 Feb, 2024
SubsTRate OxidatioN in Girls

In addition, subjective appetite will be measured throughout the assessment periods.

  • 0 views
  • 19 Feb, 2024